Clinical Trial Update: Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects [Phase 2]

View source ↗

Summary

This clinical trial update notes the Phase 2 study of HM15211 (Efocipegtrutide) for nonalcoholic steatohepatitis is ongoing but currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• HM15211 (Efocipegtrutide)

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING